2025. A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRAS-G12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland. Swiss Medical Weekly. 155, 1 (Jan. 2025), 3777. DOI:https://doi.org/10.57187/s.3777.